AI-generated summary
This review examines photobiomodulation, the use of red and near-infrared light, for retinal conditions including age-related macular degeneration, diabetic macular edema, myopia and acute retinal light injury. The authors report that clinical evidence shows improved visual activity and reduced retinal thickness after treatment, and they discuss future directions such as combination therapy and longitudinal studies.
- Who or what was studied
- Patients with retinal diseases, including age-related macular degeneration, diabetic macular edema, myopia and acute retinal light injury
- Wavelengths
- 630, 800 nm
- Limits stated in the abstract
- The abstract is a narrative review that does not report sample sizes, study counts or certainty of the clinical evidence.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on ies.ijo.cn.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 to 800 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Mitochondria, Wavelength, Age-related macular degeneration, Cytochrome c oxidase, Myopia, Retina. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.